Analysis of the short‐term curative effect of 356 cases of intraocular retinoblastoma in children. Issue 4 (8th January 2019)

• Record Type: Journal Article
• Authors: Jin, Mei; Zhao, Junyang; Zhang, Dawei; Zhang, Chengyue; Zhao, Wen; Wang, Xisi; Zhao, Qian; Duan, Chao; Su, Yan; Hong, Huimin; Ma, Xiaoli
• Is Part Of: Pediatric investigation. Volume 2:Issue 4(2018)
• Page Start: 236
• Page End: 241
• Publication Date: 2019-01-08
• Subjects: Chemotherapy -- Enucleation -- Intraocular retinoblastoma -- Local therapy; Pediatrics -- Periodicals; Pediatrics -- Research -- Periodicals; 618.920005
• DOI: 10.1002/ped4.12095
• Languages: English
• ISSNs: 2574-2272

Abstract

ABSTRACT: Importance: Retinoblastoma (Rb) is the most common primary malignant intraocular cancer in children. Systemic chemotherapy combined with local therapy is safe and effective for intraocular Rb. Objective: To summarize the short‐term outcomes of patients with Rb to provide evidence for optimizing treatment protocols and improving therapeutic safety and efficacy. Methods: The clinical data of 356 patients (486 eyes) with intraocular Rb admitted to our center from December 2009 to April 2017 were retrospectively analyzed. The measures included drug toxicity, eye‐preservation rate, and survival rate, with an emphasis on safety and short‐term efficacy. The date of last follow‐up was 30 November, 2017. Results: The patients comprised 226 unilateral Rb and 130 bilateral Rb. Enucleation before chemotherapy was performed in 72 patients. Among the 174 patients with unilateral Rb, enucleation after chemotherapy was performed in 80 patients (46.0%), and the eye was not enucleated in 89 (51.1%); 68 eyes were preserved (68/114, 59.6%) in Group D and 20 eyes (20/59, 33.8%) in Group E. Among the 220 eyes in patients with bilateral Rb, enucleation after chemotherapy was performed for 35 eyes; the eye‐preservation rate was 91.7% in Group C, 79.1% in Group D, and 52.1% in Group E. All patients developed grade II to IV myelosuppression after chemotherapy, among whom 18 patients (5%) requiring transfusion. Fourteen patients (3.9%) died of intracranial metastasis following self‐elected discontinuation of treatment ( n = 7). Patients were followed up for a median of 47 (range, 1–96) months. The expected 5‐year overall survival rate was 95.3% (96.7% for unilateral Rb and 92.9% for bilateral Rb, P = 0.074). Interpretation: The VEC (vincristine, etoposide, and carboplatin) regimen with local treatment was safe for intraocular Rb. Intracranial metastasis remains the most common cause of Rb‐related death.